FDA Warning Letter to Nexlife Over White-Labeled Compounded Semaglutide and Tirzepatide Labels
On June 8, 2026, FDA issued a warning letter to Nexlife after a March 2026 review of nexlife.us, which offers compounded semaglutide and tirzepatide products. FDA says the compounded semaglutide and tirzepatide products displayed on the site identify "Nexlife" on the pictured label, "suggesting Nexlife is the compounder of those drugs when in fact it is not," which FDA says renders the products misbranded under sections 502(a) and 502(bb) of the FD&C Act. FDA requested a written response within 15 business days.
What this meansA brand name on the vial does not mean that company made the drug — asking who actually compounds and ships a GLP-1 prescription is a basic vetting step for any telehealth service.
Source: FDA original ↗